Med Sci (Paris)
Volume 20, Number 1, Janvier 2004
|Page(s)||118 - 125|
|Published online||15 January 2004|
L’éthique de la recherche et l’usage du placebo : un état de la question au Canada
Research ethics and the use of the placebo: the state of the debate
Faculté de théologie et de sciences religieuses, Centre de recherche Université Laval Robert-Giffard, Université Laval, 2601, avenue de la Canardière, Beauport, Québec, G1J 2G3, Canada
Parmi les questions discutées en éthique de la recherche, il en est une qui resurgit de façon récurrente, c’est celle de l’usage du placebo. Cette question était au cœur des discussions précédant l’adoption de la dernière révision de la Déclaration d’Helsinki, en octobre 2000 à Édimbourg. Élaborée par l’Association médicale mondiale, la Déclaration d’Helsinki a pour objectif de fournir des recommandations destinées à guider les médecins et autres participants dans leurs recherches sur l’être humain.
The question of the use of the placebo is one of the most controversial in the field of the ethics of research today. The use of the placebo remains the standard practice of biomedical research in spite of the fact that various revisions of the Helsinki Declaration have sought to limit its use. In Canada, the Tri-council policy statement: Ethical conduct for research involving humans adopted a very restrictive position with respect to the use of placebos, precisely defining the situations in which its use would meet the demands of ethical research. The positions taken by the various ethical decision-making bodies are, however, hardly shared by regulatory bodies such as the Food and drug administration (FDA), the Council for international organization of medical sciences (CIOMS) or the European agency for the evaluation of medicinal products (EMEA). This divergence of opinions reveals two quite different conceptions of what constitutes the ethical. In the case of decision-making bodies in the ethical field, it is clearly medicine’s Hippocratic Oath which explains their reluctance to use placebos. The first responsibility of the doctor is to «do no harm» to his or her patient. This duty is inherent to the medical profession and as such is not grounded in the view of medicine as a contract for care. In the case of regulatory bodies, it is the vision of «medicine as contract» which is in view; and it is this notion that justifies the use of placebos once free and informed consent has been obtained. It is also worth noting that these regulatory bodies make frequent use of arguments based on utilitarian ends. In an unprecedented move, the World medical association published in October 2001 a clarification note about the use of placebos. An analysis of this text raises the question about its real meaning: clarification or concession ?
© 2004 médecine/sciences - Inserm / SRMS
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.